Replies to post #226848 on Biotech Values

[DewDiligence]

SLDB -14% on layoff and reprioritization:

https://finance.yahoo.com/news/solid-biosciences-announces-organizational-changes-130010015.html

In November 2019, Solid announced that the SGT-001 IGNITE DMD trial was placed on clinical hold by the U.S. Food and Drug Administration (FDA). Going forward, the company will focus on conducting its analyses of SGT-001 to determine how to address the clinical hold and resume dosing. The activities supporting the company’s other research and development programs will be curtailed as Solid establishes a path forward for SGT-001. As part of the organizational changes, the company will reduce its work force by approximately one third. In conjunction, Chief Operating Officer Alvaro Amorrortu, M.B.A. and Chief Medical Officer Jorge Quiroz, M.D., M.B.A. will depart the company but will continue as advisors to Solid.

The stock has bounced a little from its low following the announcement of a clinical hold (#msg-152236527), but it remains -65% from the closing price on 11/11/19.

[DewDiligence]

SLDB—(+70%)—FDA lifts clinical hold that’s been in effect since Nov 2019:

https://finance.yahoo.com/news/solid-biosciences-announces-fda-lifts-113000250.html